The Janssen COVID-19 Vaccine is the first single-dose vaccine regimen to ever be granted WHO emergency use listing and is now eligible for distribution via COVAX.
List view / Grid view
The European Medicines Agency's CHMP has started a rolling review of Ad26.COV2.S, Johnson & Johnson's COVID-19 vaccine.
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
The company will start enrolment to the Ad26.COV2-S vaccine trial next week, it anticipates initial results in September.
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.